



Name	Won-Mook Choi
Affiliation	Asan Medical Center, University of Ulsan College of Medicine
Country	Republic of Korea
Major Field	Hepatology (Chronic hepatitis B, hepatocellular carcinoma)

Educational Background

2004 – 2010 Seoul National University College of Medicine, Doctor of Medicine

2013 – 2015 Seoul National University College of Medicine, M.S.

2015 – 2019 KAIST Graduate School of Medical Science and Engineering, Ph.D.

Professional Experience

2004 – 2010, Intern, Seoul National University Hospital

2011 – 2015, Residency in Internal Medicine, Seoul National University Hospital

2019 – 2021, Clinical Fellow, Department of Gastroenterology, Asan Medical Center

2021 – 2022, Clinical Assistant Professor, Department of Gastroenterology, Asan Medical Center

2022 – Present, Assistant Professor, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine

2025 – Present, Treasurer, KASL

2024 – Present, Member of Publication Committee, KLCA

Main Scientific Publications

1. Heo S, Yang J, Park J, Hui RW, Song BG, Song IH, Yoon YI, Cheung TT, Chung SW, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Seto WK, Lee JH, **Choi WM (corresponding)**. Association Between Viral Replication Activity and Postoperative Recurrence of HBV-Related Hepatocellular Carcinoma. *Aliment Pharmacol Ther.* 2025 May;61(10):1680-1691.

2. Chung SW, Kim JS, **Choi WM (co-corresponding)**, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Kim KM. Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1 α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma. *Clin Cancer Res.* 2025 Feb 24. doi: 10.1158/1078-0432.CCR-24-1228.

3. **Choi WM (co-first)**, Cheuk-Fung Yip T, Lai-Hung Wong G, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Clark LJ, Jafry Z, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Baseline viral load and on-treatment hepatocellular carcinoma risk in chronic hepatitis B: A multinational cohort study. *Clin Gastroenterol Hepatol.* 2025 Feb;23(2):310-320.e7.



4. Chung SW, Um HJ, **Choi WM (corresponding)**, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC. Tenofovir is associated with a better prognosis than entecavir for hepatitis B virus-related hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2025 Feb;23(2):300-309.e9.
5. Yang J, **Choi WM (corresponding)**, Kim HD, Choi J, Yoo C, Lee D, Shim JH, Kim KM, Lim YS, Lee HC. Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma. *Liver Cancer*. 2024 Oct 16;14(2):180-192.
6. **Choi WM**, Yip TC, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Clark LJ, Jafry Z, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Wong GL, Lim YS. Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients. *Hepatology*. 2024 Aug 1;80(2):428-439.
7. **Choi WM**, Kim GA, Choi J, Choi GH, Lee YB, Sinn DH, Lim YS. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. *Gut*. 2024 Mar 7;73(4):649-658.
8. **Choi WM (co-first)**, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. *J Hepatol*. 2023 Mar;78(3):534-542.
9. **Choi WM**, Kim GA, Choi J, Han S, Lim YS. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. *J Clin Invest*. 2022 May 16;132(10):e154833.
10. **Choi WM (co-first)**, Ryu T, Lee JH, Shim YR, Kim MH, Kim HH, Kim YE, Yang K, Kim K, Choi SE, Kim W, Kim SH, Eun HS, Jeong WI. Metabotropic glutamate receptor 5 in natural killer cells attenuates liver fibrosis by exerting cytotoxicity to activated stellate cells. *Hepatology*. 2021 Oct;74(4):2170-2185.
11. **Choi WM**, Kim HH, Kim MH, Cinar R, Yi HS, Eun HS, Kim SH, Choi YJ, Lee YS, Kim SY, Seo W, Lee JH, Shim YR, Kim YE, Yang K, Ryu T, Hwang JH, Lee CH, Choi HS, Gao B, Kim W, Kim SK, Kunos G, Jeong WI. Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis. *Cell Metab*. 2019 Nov 5;30(5):877-889.e7.